Transpupilary thermotherapy of occult subfoveal choroidal neovascularization secondary to age related macular degeneration
Authors
Abstract:
Abstract Background: Transpupillary thermotherapy is a new treatment for subfoveal choroidal neovascularization which needs further evaluation. This study was aimed to evaluate the efficacy of transpupillary thermotherapy on regression of occult subfoveal choroidal neovascularization with or without pigment epithelial detachment in patients with age-related macular degeneration. Methods: In a case series study, patients with age-related macular degeneration who had occult subfoveal choroidal neovascularization less than 4 disc diameters with or without pigment epithelial detachment underwent transpupillary thermotherapy by diode laser. The patients were followed for 1-12 months. Main outcome measures were visual acuity changes, flattening of pigment epithelial detachment observed clinically, or absence of leakage in angiography. The data were analyzed using T-test and chi- square. Results: The study included 30 eyes of 30 patients. Mean age of the patients was 67±7 years. Mean follow up time was 5.3±0.5 months. Visual acuity improved in 63%, remained unchanged in 20%, and worsened in 17%. Mean visual acuity improved from 1.25±0.4 log MAR (20/320) to 1.06±0.36 log MAR (20/200), (p<0.04). Choroidal atrophy or flat scar was achieved in 73% and failure to treatment was seen in 27%, (p =0.0001). Pigment epithelial detachment flattened in all cases after transpupillary thermotherapy. Conclusion: Transpupillary thermotherapy may be a particularly useful modality for treating occult subfoveal choroidal neovascularization associated with serous pigment epithelial detachment in selected cases of age-related macular degeneration.
similar resources
transpupilary thermotherapy of occult subfoveal choroidal neovascularization secondary to age related macular degeneration
abstract background: transpupillary thermotherapy is a new treatment for subfoveal choroidal neovascularization which needs further evaluation. this study was aimed to evaluate the efficacy of transpupillary thermotherapy on regression of occult subfoveal choroidal neovascularization with or without pigment epithelial detachment in patients with age-related macular degeneration. methods: in a c...
full textTRANSPUPILLARY THERMOTHERAPY (TTT): A novel approach in the treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration
Dr. Ashish Vaidya Vitreo-retinal Consultant, Bombay City Eye Institute. Dr. Jigisha Shah Fellow, Bombay City Eye Institute INTRODUCTION: ARMD is a leading cause of central vision loss in patients older than 50 years of age. The majority of eyes suffer severe vision loss as a result of choroidal neovascularization, the only proven effective treatment for which is laser photocoagulation. The Macu...
full textBevacizumab for occult subfoveal neovascularization in age-related macular degeneration.
PURPOSE To report on the treatment of exudative age-related macular degeneration by intravitreal bevacizumab (Avastin). METHODS A 78-year-old patient experienced a progressive loss of visual acuity in her right eye due to an occult subfoveal neovascular membrane in age-related macular degeneration. She received an intravitreal injection of 1.5 mg bevacizumab. RESULTS Within 4 weeks after th...
full textPhotodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration.
BACKGROUND To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS We retrospectively reviewed the chart records and fluorescein angiography of patients with subfoveal CNV who were treated with verteporfin PDT between September 2001 and March 2003 an...
full textChoroidal neovascularization and age-related macular degeneration.
and dysfunctional RPE are thought to be pivotal.66 CSR is a common maculopathy that can adversely affect central visual function and is 6-fold more common in males than females.67 Affected patients are typically between 30 and 50 years of age. Many putative risk factors exist for the development of CSR, the most conclusive being any form of exogenous corticosteroid use. Other risk factors inclu...
full textMy Resources
Journal title
volume 20 issue 4
pages 175- 180
publication date 2007-02
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023